470 related articles for article (PubMed ID: 28633480)
21. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
[TBL] [Abstract][Full Text] [Related]
22. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
23. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
25. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection.
Bayarri-Lara C; Ortega FG; Cueto Ladrón de Guevara A; Puche JL; Ruiz Zafra J; de Miguel-Pérez D; Ramos AS; Giraldo-Ospina CF; Navajas Gómez JA; Delgado-Rodriguez M; Lorente JA; Serrano MJ
PLoS One; 2016; 11(2):e0148659. PubMed ID: 26913536
[TBL] [Abstract][Full Text] [Related]
27. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
28. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated With First-Line EGFR Tyrosine Kinase Inhibitors.
Jiang T; Zhao J; Zhao C; Li X; Shen J; Zhou J; Ren S; Su C; Zhou C; O'Brien M
Clin Lung Cancer; 2019 Mar; 20(2):124-133.e2. PubMed ID: 30587399
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR-T790M mutant non-small cell lung cancer patients.
Yang B; Zheng D; Zeng Υ; Qin A; Gao J; Yu G
J BUON; 2018; 23(4):1077-1081. PubMed ID: 30358214
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
32. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
Szpechcinski A; Florczuk M; Duk K; Zdral A; Rudzinski S; Bryl M; Czyzewicz G; Rudzinski P; Kupis W; Wojda E; Giedronowicz D; Langfort R; Barinow-Wojewodzki A; Orlowski T; Chorostowska-Wynimko J
Cell Mol Life Sci; 2019 Sep; 76(18):3641-3656. PubMed ID: 30953094
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
34. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Marchetti A; Del Grammastro M; Felicioni L; Malatesta S; Filice G; Centi I; De Pas T; Santoro A; Chella A; Brandes AA; Venturino P; Cuccurullo F; Crinò L; Buttitta F
PLoS One; 2014; 9(8):e103883. PubMed ID: 25137181
[TBL] [Abstract][Full Text] [Related]
35. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
[TBL] [Abstract][Full Text] [Related]
36. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
[TBL] [Abstract][Full Text] [Related]
37. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
[TBL] [Abstract][Full Text] [Related]
38. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma.
He W; Xu D; Wang Z; Wu H; Xiang X; Tang B; Jiang W; Cui Y; Wang H; Jiang N; Sun Y; Chen Y; Li S; Hou M; Zhang Y; Wang L; Ke ZF
J Transl Med; 2019 Jan; 17(1):32. PubMed ID: 30658713
[TBL] [Abstract][Full Text] [Related]
39. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
[TBL] [Abstract][Full Text] [Related]
40. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
Watanabe M; Kenmotsu H; Ko R; Wakuda K; Ono A; Imai H; Taira T; Naito T; Murakami H; Abe M; Endo M; Nakajima T; Koh Y; Takahashi T
Cancer Sci; 2018 Aug; 109(8):2539-2548. PubMed ID: 29900633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]